Skip to main
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid is well-positioned for future success with their proprietary drug delivery technology, PLEX, and strong partnerships and advancements for their product candidates. Despite challenges such as clinical and financing risks, a positive outcome of FDA interactions and potential approval of D-PLEX100 in 4Q26 could significantly increase PolyPid's value and support a $9 per share price target.

Bears say

PolyPid is a clinical-stage biopharmaceutical company that has potential in its D-PLEX technology platform and new Kynatrix technology, but it remains uncertain whether the company can successfully navigate the FDA's pre-approval inspection, which could be a key bottleneck. Despite reporting better-than-expected financials for the third quarter of 2025, the company still has a net loss and may need to raise additional funds to support its operations beyond 2026. The upcoming pre-NDA meeting in December 2025 may provide clarity on the potential commercial manufacturing and labeling for D-PLEX100, but questions remain around its indications and potential site inspections during initial batches.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.